Document is current
Any future updates will be listed below
-
Authors
Carretero-Barrio, Irene https://orcid.org/0000-0003-1986-2965
Pijuan, Lara https://orcid.org/0000-0002-9978-6933
Illarramendi, Adrián
Curto, Daniel https://orcid.org/0000-0001-6133-1864
López-Ríos, Fernando https://orcid.org/0000-0001-6813-0395
Estébanez-Gallo, Ángel
Castellvi, Josep
Granados-Aparici, Sofía
Compañ-Quilis, Desamparados
Noguera, Rosa https://orcid.org/0000-0003-4546-7459
Esteban-Rodríguez, Isabel
Sánchez-Güerri, Ignacio
Ramos-Guerra, Ana Delia https://orcid.org/0000-0003-3203-9906
Ortuño, Juan Enrique https://orcid.org/0000-0001-6636-602X
Garrido, Pilar https://orcid.org/0000-0002-5899-6125
Ledesma-Carbayo, María Jesús https://orcid.org/0000-0002-8307-0017
Benito, Amparo https://orcid.org/0000-0002-1312-4892
Palacios, José https://orcid.org/0000-0002-6730-5066
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia, Innovación y Universidades (PID2022-141493OB-I00)
Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00316)
Instituto de Salud Carlos III (PMP21/00107)
Instituto de Salud Carlos III (PI22-01700)
Comunidad de Madrid (P2022/BMD-7437)
Fundación Mutua Madrileña (AP18051-2022)
- License Information
-
More Information
Article History
Received: 4 January 2024
Accepted: 3 October 2024
First Online: 15 October 2024
Declarations
:
: PG declares consultancy/honoraria from Abbvie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda. Direct funding from Medscape and Touch Medical.The remaining authors declare no competing interests. The remaining authors declare no competing interests.
